Monitor Antiobesity Drug Dosing After Rapid Weight Loss

A patient who developed atrial fibrillation resulting from the failure to adjust their levothyroxine dose after rapid, significant weight loss while on the antiobesity drug tirzepatide (Zepbound) serves as a key reminder in managing patients experiencing rapid weight loss, either from antiobesity medications or any other means: Patients taking medications with weight-based dosing need to have their doses closely monitored.